Business Wire

OSE Immunotherapeutics Receives First Notice of Allowance of a Patent for Use of Tedopi® to Treat Brain Metastasis

NANTES, France--(BUSINESS WIRE)--Regulatory News: OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), today announced that the Japanese Patent Office has issued the notice of ...
Business Wire

OSE Immunotherapeutics Expands its Collaboration with MAbSilico to Use Artificial Intelligence to Accelerate Drug Development of Novel Antibody Therapeutics

OSE is advancing an "Immunotherapy 2.0" future by leveraging MAbSilico’s artificial intelligence-powered software solutions and professional services to accelerate and further optimize the development ...
Business Insider

OSE Immunotherapeutics Announces Strategic Multi-Year Research Collaboration with Memorial Sloan Kettering Cancer Center in New YorkFocused on Company’s Cytotoxic Monoclonal ...

NANTES, France, June 12, 2017 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics SA (ISIN: FR0012127173);(Mnémo:OSE) today announced that the Company has entered into a multi-year research collaboration on ...